100Plus Raises $1.25M From Greylock and Band Of Angels To Make You Live Longer
Less than a month after securing $500K from Founders Fund, health prediction service 100Plus has brought its funding up to $1.25 million. The new $750K in funding comes from Reid Hoffman and John Lilly via …
Context & Ripple Effects
100Plus is stacking rounds at unusual speed: less than a month after a $500K check from Founders Fund, the health prediction service has added $750K from Reid Hoffman and John Lilly via Greylock and Band Of Angels, bringing its total to $1.25 million.
The names matter as much as the amounts. Hoffman ranked #3 on the 2011 Midas List and has become Silicon Valley's go-to adviser and connector for early startups, so his personal participation signals more than a routine angel fill-on.
First-order effects
- 100Plus leaves November with $1.25 million and two marquee backers attached, giving a pre-product health prediction service both runway and credibility it did not have in October.
- Founders Fund's early bet is effectively co-signed: Hoffman and Lilly's entry within weeks de-risks the deal in the eyes of the next tier of investors.
Second-order effects
- Rival consumer-health and quantified-self startups now face a bar set by Midas-list angels writing personal checks early, pressuring other seed investors to move faster on comparable deals rather than wait for traction.
- Hoffman's reputation as the Valley's connection hub means 100Plus gains access to networks — talent, partners, follow-on buyers — that money alone would not buy.
Third-order effects
- If top-ranked angels keep seeding consumer health-data companies with personal capital before institutional funds commit, the category's earliest valuations get set by individual reputations rather than fund mandates — a structure Silicon Valley has seen repeat across consumer verticals.
The trend: Silicon Valley's highest-profile angels are using personal checks to stake claims in consumer health prediction while the space is still too early for dedicated institutional health-tech capital.